IRONWOOD PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $19.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-16.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2024-02-16
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-06-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2023-03-31 was $19.00K.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $19.00K, a 98.54% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $1.30M, a 87.96% decline from fiscal 2021.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $10.77M.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was -$12.17M, a 174.99% decline from fiscal 2019.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $0.00 derived: sum of 2 quarters · filed 2024-02-16 | $0.00 derived: sum of 3 quarters · filed 2024-02-16 | $19.00K 10-K · filed 2024-02-16 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $19.00K 10-Q · filed 2023-11-09 | $2.63M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $19.00K 10-Q · filed 2023-08-09 | $2.63M derived: sum of 3 quarters · filed 2024-02-16 | $2.48M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2023-03-31 | $19.00K 10-Q · filed 2023-05-04 | $2.63M derived: sum of 2 quarters · filed 2024-02-16 | $2.48M derived: sum of 3 quarters · filed 2024-02-16 | $1.73M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2022-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $2.46M derived: sum of 2 quarters · filed 2024-02-16 | $1.71M derived: sum of 3 quarters · filed 2024-02-16 | $1.30M 10-K · filed 2024-02-16 | |
| 2022-09-30 | -$151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$898.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.31M 10-Q · filed 2022-11-03 | $16.06M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2022-06-30 | -$747.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.16M 10-Q · filed 2022-08-04 | $16.21M derived: sum of 3 quarters · filed 2023-02-16 | $8.58M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2022-03-31 | -$417.00K 10-Q · filed 2022-05-05 | $16.95M derived: sum of 2 quarters · filed 2023-02-16 | $9.33M derived: sum of 3 quarters · filed 2023-02-16 | $6.25M derived: sum of 4 quarters · filed 2023-02-16 | |
| 2021-12-31 | $17.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $9.74M derived: sum of 2 quarters · filed 2023-02-16 | $6.66M derived: sum of 3 quarters · filed 2023-02-16 | $10.77M 10-K · filed 2023-02-16 | -$10.77M 10-K · filed 2022-02-18 |
| 2021-09-30 | -$7.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$10.71M derived: sum of 2 quarters · filed 2021-11-04 | -$6.60M 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | -$3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.03M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $4.11M 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | -$12.17M 10-K · filed 2022-02-18 | ||||
| 2019-12-31 | $16.23M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |